Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities (2017 - 2026)

Crinetics Pharmaceuticals' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $389.9 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 8686.91% year-over-year to $389.9 million; the TTM figure through Mar 2026 stood at $426.0 million (down 31.89% YoY), while the FY2025 annual figure was $40.6 million, down 96.0% from the prior year.
• Cash from Financing Activities was $389.9 million for Q1 2026 at Crinetics Pharmaceuticals, up from $26.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $556.2 million in Q4 2024 to a low of $115000.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $115.2 million across 5 years, with a median of $12.7 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 99.93% in 2022, then surged 81216.94% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $115000.0 in 2022, then surged by 34870.43% to $40.2 million in 2023, then soared by 1283.12% to $556.2 million in 2024, then slumped by 95.32% to $26.0 million in 2025, then soared by 1397.5% to $389.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $389.9 million (Q1 2026), $26.0 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.